U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H27N3O6
Molecular Weight 393.4342
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAPRODUSTAT

SMILES

OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C3CCCCC3)C1=O

InChI

InChIKey=RUEYEZADQJCKGV-UHFFFAOYSA-N
InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,15H,1-11H2,(H,20,25)(H,23,24)

HIDE SMILES / InChI

Molecular Formula C19H27N3O6
Molecular Weight 393.4342
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Daprodustat (DUVROQ) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease (CKD). Inhibition of PHD prevents degradation of hypoxia-inducible factor (HIF), leading to the production of erythropoietin and subsequent induction of erythropoiesis. In June, daprodustat received its first approval in Japan for the treatment of renal anaemia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.5 nM [IC50]
22.2 nM [IC50]
5.5 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
JESDUVROQ

Approved Use

JESDUVROQ is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months

Launch Date

2023
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
140 ng/mL
10 mg 3 times / week steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DAPRODUSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
247 ng/mL
25 mg 3 times / week steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DAPRODUSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
387 ng/mL
30 mg 3 times / week steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DAPRODUSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
348 ng × h/mL
10 mg 3 times / week steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DAPRODUSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1214 ng × h/mL
25 mg 3 times / week steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DAPRODUSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1369 ng × h/mL
30 mg 3 times / week steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DAPRODUSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.1 h
10 mg 3 times / week steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DAPRODUSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.4 h
25 mg 3 times / week steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DAPRODUSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.9 h
30 mg 3 times / week steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DAPRODUSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes [IC50 11 uM]
yes [IC50 21 uM]
yes [IC50 6 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Gemfibrozil increased Cmax and AUCinf by 3.9-fold and 18.6-fold.
Page: 71.0
minor
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
yes
yes
yes
yes
yes
yes
Tox targets
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Targeting the hypoxia-sensing pathway in clinical hematology.
2014-02
First-in-class anemia drug takes aim at Amgen's dominion.
2013-11
Patents

Patents

Sample Use Guides

0.5, 2, and 5 mg once-daily for 4-week treatment
Route of Administration: Oral
Human CP4H/Cofactor mix (4X final concentration in 50 mM HEPES, pH 7.5 with 50 mM KCl) was incubated at room temperature for 30 minutes with GSK1278863 (10 point, 3-fold serial dilution in 50% DMSO, 15X final concentration) or 50% DMSO. Substrate mix (1.4X final concentration in 50 mM HEPES, pH 7.5 with 50 mM KCl) was added to the plate yielding a 32 μL final reaction volume. After 20 minutes, the reaction was quenched by the addition of 0.67% final H3PO4. Product formation was detected using Reverse Phase High Performance Liquid Chromatography (HPLC; Ex 336nM and Em 517 nM). Final concentrations of the CP4H/Cofactor mix were 21.11 nM enzyme, 1 mg/mL BSA, 50 μM FeCl2, 2 mM ascorbic acid, 100 μM DTT, and 100 μg/mL catalase. The substrate mix consisted of 100 μM dansyl-GFPG-Oet, and 110 μM α-ketoglutarate. Percent inhibition data were determined from the ratio of product to substrate after a 20 minute reaction. The IC50 value was determined by fitting the percent inhibition data to a two-parameter IC50 equation.
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:31:48 GMT 2025
Edited
by admin
on Wed Apr 02 08:31:48 GMT 2025
Record UNII
JVR38ZM64B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
daprodustat [INN]
Preferred Name English
DAPRODUSTAT
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
Daprodustat [WHO-DD]
Common Name English
DAPRODUSTAT [JAN]
Common Name English
GLYCINE, N-((1,3-DICYCLOHEXYLHEXAHYDRO-2,4,6-TRIOXO-5-PYRIMIDINYL)CARBONYL)-
Systematic Name English
DAPRODUSTAT [USAN]
Common Name English
N-[(1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl]glycine
Systematic Name English
GSK1278863
Code English
JESDUVROQ
Brand Name English
GSK-1278863
Code English
Code System Code Type Description
WIKIPEDIA
Daprodustat
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
DAILYMED
JVR38ZM64B
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
DRUG BANK
DB11682
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
FDA UNII
JVR38ZM64B
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
EPA CompTox
DTXSID501337360
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
EVMPD
SUB185070
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
USAN
BC-163
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
PUBCHEM
91617630
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
INN
10167
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
NCI_THESAURUS
C169877
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
CAS
960539-70-2
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
ChEMBL
CHEMBL3544988
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
SMS_ID
100000170880
Created by admin on Wed Apr 02 08:31:48 GMT 2025 , Edited by admin on Wed Apr 02 08:31:48 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY